FDA: Novartis Arthritis Drug 'Highly Similar' to Amgen's Enbrel
The injection is used to treat five chronic inflammatory conditions, including rheumatoid arthritis and plaque psoriasis. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 12, 2016 Category: Pharmaceuticals Source Type: news
Novartis copy of Amgen arthritis drug highly similar: FDA staff
(Reuters) - Novartis AG's cheaper version of Amgen Inc's blockbuster arthritis drug Enbrel is highly similar in potency and safety to the original, according to a review by Food and Drug Administration staff. (Source: Reuters: Health)
Source: Reuters: Health - July 11, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Etanercept Showing Promise in Erosive Hand OsteoarthritisEtanercept Showing Promise in Erosive Hand Osteoarthritis
Cytokine-directed therapy can ameliorate pain and structural damage in some patients with erosive osteoarthritis of the hands, new research shows. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 16, 2016 Category: Consumer Health News Tags: Rheumatology News Source Type: news
Anti-TNF study sheds new light on how they function
In this study, the researchers observed that treating rheumatoid arthritis patients with adalimumab helped to increase the number of regulatory T cells that suppressed inflammation in the body. It was previously assumed that this was because TNF stops the development of these anti-inflammatory cells.However, the new study revealed that in actual fact, TNF actually triggers the formation of anti-inflammatory T cells, and that adalimumab is capable of enhancing this process at the same time as stopping TNF's pro-inflammatory effects.Michael Ehrenstein and colleagues at University College London said: "These results ...
Source: Arthritis Research UK - June 7, 2016 Category: Rheumatology Source Type: news
Hunting growth, Samsung races to get up to speed on biosimilar drugs
SEOUL (Reuters) - As Samsung Bioepis raced to be first to market with a copy of Enbrel, a blockbuster rheumatoid arthritis drug, countdown clocks reminded workers - heading for lunch, meetings or even the washroom - of the days to the first mass production run. (Source: Reuters: Health)
Source: Reuters: Health - June 6, 2016 Category: Consumer Health News Tags: healthNews Source Type: news
Etanercept/methotrexate treatment for rheumatoid arthritis 'can be safely tapered'
This study adds to the growing body of evidence that in some patients who have responded well to treatment, doses could be reduced or even stopped altogether without them experiencing a change in effect. This work is still in the early stages, and it is important that people with arthritis consult their rheumatologist before reducing dosage of any prescribed medication." (Source: Arthritis Research UK)
Source: Arthritis Research UK - June 6, 2016 Category: Rheumatology Source Type: news
Inflammation May Hold Key to Cognitive Decline in Alzheimer's Disease
A new study poses an intriguing question: Does gum disease accelerate cognitive decline in the early stages of Alzheimer's disease? The answer may be found in inflammation.
Aging affects our immune system, and inflammation is a normal part of the body's immune response to infection or injury. Previous studies have shown that the inflammation response increases as we age. Inflammation is now linked to a number of diseases more common in people over age 65, including atherosclerosis, osteoarthritis and Alzheimer's.
In a recent study, Professor Clive Holmes of the University of Southampton (UK), along with colleagues from K...
Source: Science - The Huffington Post - May 3, 2016 Category: Science Source Type: news
First-line etanercept reduces costs of RA in Japan
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 30, 2016 Category: Drugs & Pharmacology Source Type: news
MTX Dose Can Be Kept Low When Combined With Enbrel in RA (CME/CE)
(MedPage Today) -- No extra benefit from high methotrexate doses in combo treatment (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 30, 2016 Category: Primary Care Source Type: news
Amgen's First Quarter 2016 Revenues Increased 10 Percent To $5.5 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $2.90
First Quarter 2016 GAAP EPS Were $2.50
2016 Total Revenues and Adjusted EPS Guidance Increased to $22.2-$22.6 Billion and $10.85-$11.20, Respectively
THOUSAND OAKS, Calif., April 28, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2016. Key results include:
Total revenues increased 10 percent versus the first quarter of 2015 to $5,527 million, with 7 percent product sales growth driven by Enbrel® (etanercept), Prolia® (denosumab), Aranesp® (darbepoetin alfa), Neulasta® (pegfilgrastim), Kyprolis® (carfilzomib) and XGEVA® (denosumab).
Adjusted EPS grew 1...
Source: Amgen News Release - April 28, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
New rheumatoid arthritis drug 'can succeed where others fail'
A new therapy for rheumatoid arthritis has shown potential to effectively treat patients who have failed to respond to other types of therapy.The new drug, baricitinib, is currently still in the clinical testing phase, but if approved it could represent a promising new therapeutic option for people with refractory rheumatoid arthritis, who currently have few options available to them.A new treatment approach Baricitinib was tested in a phase III clinical trial, led by Stanford University in the US and the Medical University of Vienna in Austria, to determine the drug's effectiveness in patients who had not benefited fr...
Source: Arthritis Research UK - April 5, 2016 Category: Rheumatology Source Type: news
New study highlights long-term tolerability of anti-TNF therapies
This study provides reassuring evidence that anti-TNF therapies are effective in some patients over long periods of time; however, it also highlights the importance of selecting the right drug for each patient, as a large number of people with arthritis have to switch between therapies during a course of treatment."We are funding research which aims to help doctors predict which patients will respond best to which therapies, helping to speed up the time it takes to get the right treatment to the right patient." (Source: Arthritis Research UK)
Source: Arthritis Research UK - April 3, 2016 Category: Rheumatology Source Type: news
Benefits of anti-TNF treatment for psoriatic arthritis highlighted by study
This study was significant as it utilised data from patients in a real-world setting, rather than controlled test conditions. This provides doctors with a clearer view of how drugs work in routine clinical practice.A total of 420 biologic-naive patients with psoriatic arthritis, who were beginning treatment with the anti-TNF therapies adalimumab, etanercept or infliximab, were enrolled in the trial, with their progress followed over four years.Attention was paid to drug survival rates - the number of people remaining on treatment after a given period - as well as how many of the patients continued to rely on glucocorticoid...
Source: Arthritis Research UK - March 28, 2016 Category: Rheumatology Source Type: news
FDA Accepts Amgen's Supplemental Biologics License Application For The Expanded Use Of Enbrel® (Etanercept) To Treat Pediatric Patients With Chronic Severe Plaque Psoriasis
THOUSAND OAKS, Calif., March 10, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Amgen's supplemental Biologics License Application (sBLA) for the expanded use of Enbrel® (etanercept) to treat pediatric patients with chronic severe plaque psoriasis.
"If approved, ENBREL would be the first systemic drug approved in the U.S. to treat chronic severe plaque psoriasis in pediatric patients," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "We hope to be able to provide pediatric patients with an import...
Source: Amgen News Release - March 10, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
